BMY’s Latest Twist: What’s Fueling the Unexpected Shifts in Bristol-Myers Squibb Co’s Stock Price?
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at $51.
30m
To mark the 10th anniversary of its Global Patient Week, Bristol Myers Squibb, a leading global biopharmaceutical company, ...
Prime Medicine, founded by David Liu, is finding that the path of translating scientific breakthroughs to treatments is ...
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
The high-profile biotech is zeroing in on programs that serve as proof points for its technology, while seeking partners for ...
Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell therapies. Prime, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback